Related Experiment Video

Updated: May 28, 2026

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
08:55

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia

Published on: November 30, 2016

The role of myostatin in muscle wasting: an overview

Yulia Elkina, Stephan von Haehling, Stefan D Anker

    Journal of Cachexia, Sarcopenia and Muscle
    |October 4, 2011
    PubMed

    Insights

    Myostatin negatively regulates muscle mass. Understanding myostatin signaling pathways is crucial for developing new therapies to combat muscle wasting in cachexia.

    Area of Science:

    • Biochemistry
    • Molecular Biology
    • Physiology

    Background:

    • Myostatin is a key cytokine regulating skeletal muscle mass.
    • It acts by upregulating atrogenes and downregulating myogenesis genes.
    • Muscle size is influenced by myostatin signaling and the IGF-1/PI3K/Akt pathway.

    Purpose of the Study:

    • To review current knowledge on myostatin signaling pathways.
    • To explore therapeutic strategies targeting myostatin for cachexia treatment.

    Main Methods:

    • Literature review of myostatin signaling.
    • Analysis of therapeutic approaches for cachexia.

    Main Results:

    • Myostatin signaling is complex and not fully understood.
    • Myostatin upregulation is implicated in muscle wasting diseases like cancer and heart failure.
    • Targeting myostatin presents a promising therapeutic avenue for cachexia.

    Conclusions:

    • Further characterization of myostatin signaling is essential for cachexia treatment development.
    • Regulation of myostatin and its targets offers potential therapeutic benefits.

    More Related Videos

    Myo-mechanical Analysis of Isolated Skeletal Muscle08:42

    Myo-mechanical Analysis of Isolated Skeletal Muscle

    Published on: February 22, 2011

    Preparation of Primary Myogenic Precursor Cell/Myoblast Cultures from Basal Vertebrate Lineages07:51

    Preparation of Primary Myogenic Precursor Cell/Myoblast Cultures from Basal Vertebrate Lineages

    Published on: April 30, 2014

    Related Concept Videos

    Disorders of the Skeletal Muscle01:28

    Disorders of the Skeletal Muscle

    The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
    Musculoskeletal disorders
    Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
    Formation of Muscle Fibers from Myoblasts01:13

    Formation of Muscle Fibers from Myoblasts

    De novo myogenesis, or the formation of muscle fibers, begins during the early embryonic stages. The skeletal muscle is formed from somites– blocks of embryonic cell layers. The somites are further divided into dermatomes, myotomes, sclerotomes, and syndetomes. Among these, the myotomes give rise to muscle fibers.
    Muscle progenitor cells (MPCs) are formed from the myotomes. MPCs express genes that encode the transcription factors Pax3 and Pax7. Along with Pax 3/7, other transcription factors...
    Satellite Stem Cells and Muscular Dystrophy01:21

    Satellite Stem Cells and Muscular Dystrophy

    Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
    Myasthenia Gravis: Overview and Treatment01:20

    Myasthenia Gravis: Overview and Treatment

    Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
    These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
    Overview of Skeletal Muscle01:15

    Overview of Skeletal Muscle

    Skeletal muscles are composed of a bundle of muscle fibers and are attached to bones through tendons. Each skeletal muscle fiber is a single muscle cell. The sarcolemma, the plasma membrane of a skeletal muscle cell, consists of a lipid bilayer and glycocalyx that supports muscle fibers. The sarcolemma extends into the muscle cells to form tubular structures called transverse or T-tubules. Each side of the T-tubules consists of a membrane-bound structure called the sarcoplasmic reticulum,...
    Myasthenia Gravis ll: Pathophysiology01:22

    Myasthenia Gravis ll: Pathophysiology

    The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...